Vivoryon Therapeutics NV (FRA:05Y) EBIT: €-8.81 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:05Y Vivoryon Therapeutics NV FRA:05Y
38 GF Score
Price €1.17
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV EBIT?

Vivoryon Therapeutics NV FRA:05Y -0.43% 38 EBIT is €-8.81 Mil as of Dec. 2025. GuruFocus rates FRA:05Y with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Vivoryon Therapeutics NV's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-3.36 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vivoryon Therapeutics NV's annualized ROC % for the quarter that ended in Dec. 2025 was -471.35%. Vivoryon Therapeutics NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -6,337.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vivoryon Therapeutics NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -28.79%.

Vivoryon Therapeutics NV  (FRA:05Y) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vivoryon Therapeutics NV's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-6.778 * ( 1 - 0% )/( (1.449 + 1.427)/ 2 )
=-6.778/1.438
=-471.35 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6.419 - 1.025 - ( 4.867 - max(0, 1.299 - 5.244+4.867))
=1.449

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.518 - 0.501 - ( 5.64 - max(0, 0.837 - 6.427+5.64))
=1.427

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Vivoryon Therapeutics NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.718/( ( (0.089 + max(-0.861, 0)) + (0.121 + max(0.0020000000000003, 0)) )/ 2 )
=-6.718/( ( 0.089 + 0.123 )/ 2 )
=-6.718/0.106
=-6,337.74 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.377) - (1.025 + 0 + 0.213)
=-0.861

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.775) - (0.501 + 0 + 0.272)
=0.0020000000000003

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vivoryon Therapeutics NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-8.808/30.597
=-28.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV EBIT Related Terms

Vivoryon Therapeutics NV EBIT Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV EBIT Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.20 -28.33 -28.52 -20.52 -8.81

Vivoryon Therapeutics NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.79 -13.51 -7.02 -5.45 -3.36

FRA:05Y vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Vivoryon Therapeutics NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's EV-to-EBIT falls into.


FRA:05Y
38GF Score
Vivoryon Therapeutics NV FRA:05Y
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-8.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-8.81 Mil mean?
Vivoryon Therapeutics NV (FRA:05Y) has a EBIT of €-8.81 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vivoryon Therapeutics NV.
Is Vivoryon Therapeutics NV's EBIT too high?
Vivoryon Therapeutics NV's current EBIT is €-8.81 Mil. Overall, Vivoryon Therapeutics NV has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's EBIT compare to VRTX and REGN?
Vivoryon Therapeutics NV's EBIT of €-8.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vivoryon Therapeutics NV. Vivoryon Therapeutics NV's current EBIT is €-8.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (FRA:05Y) has a current EBIT of €-8.81 Mil. The current EBIT is €-8.81 Mil. Vivoryon Therapeutics NV's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vivoryon Therapeutics NV (FRA:05Y), the current EBIT is €-8.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
38GF Score

Get the complete analysis for FRA:05Y

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price